Development of new therapies based on the stimulation of the anti-cancer activity of the immune system

OncoArendi Therapeutics as the leader of a scientific and industrial consortium obtained funding in an amount of over PLN 25.5 million as part of the second competition of the National Center for Research and Development in the program STRATEGMED "PREVENTION AND TREATMENT OF CIVILIZATIONAL DISEASES". The Medical University of Warsaw is a beneficiary of this funding as a member of the consortium implementing the DIMUNO project. The aim of the project is to develop a new approach in targeted cancer therapy based on world-unique inhibitors of enzymes that protect cancer cells against the body's immune response. The developed compounds will inhibit the activity of enzymes that break down arginine and tryptophan. New therapeutic strategies will be developed by an interdisciplinary scientific and industrial consortium conducting research in the fields of medical chemistry, biochemistry, biotechnology, nanotechnology, immunology and medicine. The result of the project will be the development of a new molecule - a candidate for clinical trials for the treatment of many types of cancer. The selection of a clinical candidate will take place in a parallel search for inhibitors of several enzymes, including the use of nanocarriers. The full composition of the consortium participating in the project is: OncoArendi Therapeutics Sp. z o.o., Medical University of Warsaw, M. Nencki Institute of Experimental Biology of the Polish Academy of Sciences, Institute of Biochemistry and Biophysics of the Polish Academy of Sciences, International Institute of Experimental and Cell Biology, private partners Nanovelos Sp. z o. o. and Scanmed S. A.